ARCTURUS THERAPEUTICS HOLDINGS INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $11.37 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-03-03
- ARCTURUS THERAPEUTICS HOLDINGS INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $11.37, a 49.73% decline from fiscal 2024.
- ARCTURUS THERAPEUTICS HOLDINGS INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $22.62, a 17.38% decline from fiscal 2023.
- ARCTURUS THERAPEUTICS HOLDINGS INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $27.38, a 23.00% increase from fiscal 2022.
- ARCTURUS THERAPEUTICS HOLDINGS INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $22.26, a 46.84% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|
| 2025-12-31 | $11.37 10-K · filed 2026-03-03 | |
| 2024-12-31 | $22.62 10-K · filed 2025-03-06 | |
| 2023-12-31 | $27.38 10-K · filed 2024-03-14 | |
| 2022-12-31 | $22.26 10-K · filed 2023-03-29 | |
| 2021-12-31 | $41.87 10-K · filed 2022-03-01 | |
| 2020-12-31 | $66.91 10-K · filed 2021-03-01 | |
| 2019-12-31 | $7.81 10-K · filed 2020-03-16 | |
| 2019-06-30 | $5.82 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |